Neuronostics are delighted to announce that Anne Hyland is joining our team as Non-Executive Director and Chair of the Board of Directors.
Anne brings with her over 25 years of commercial and financial experience with an extremely strong track record in the medical industry. Since March 2015, Anne has been Chief Financial Officer & Company Secretary of Kymab Group Ltd, a biopharmaceutical company whose shareholders included the Welcome Trust and the Bill & Melinda Gates Foundation. In 2021, Kymab was acquired by Sanofi for US$1.1 billion and deferred consideration of up to US $350m. Additionally, Anne served as Chief Financial Officer of BBI Diagnostics Group Ltd, a diversified global diagnostics business, and Vectura Group plc, a company which develops products and devices to treat respiratory diseases.
Anne has proven to be a strong supporter of Neuronostics’ mission, saying: “Neuronostics are looking to radically improve the lives of people living with epilepsy and many other neurological conditions. This is a journey I want to be a part of and I look forward to working with the team”
Anne also has experience serving as Non-Executive Director and Chair of the Audit Committee of several biopharmaceutical and services companies, including Clinigen Group Plc and Mereo BioPharma Plc, and a global specialty chemicals company Elementis Plc. Previously, she held a number of senior finance positions, including Director of Corporate Finance at the then FTSE 100 Celltech Group plc, Medeva Plc and KPMG. Anne is a Chartered Accountant (FCA), a Corporate Tax Adviser (CTA–AITI) and holds a degree in business studies from Trinity College, Dublin.
As Neuronostics’ Managing Director, John Terry, described: “Anne has deep commercial and financial expertise, as well as significant experience of enabling start-ups to scale rapidly. At Neuronostics, we are excited to work with Anne as we develop our commercial strategy and our route to market over the next 24 months.”
From everyone at Neuronostics, we would like to welcome Anne to the team and look forward to leveraging her knowledge, expertise and experience to help us in the next phase of our company’s journey.